Boehringer Ingelheim Pharmaceuticals Inc. et al v. Hetero USA Inc. et al
| Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Corporation and Boehringer Ingelheim Pharma GmbH & Co. KG |
| Hetero USA Inc., Hetero Labs Limited Unit-V and Hetero Labs Limited |
| 1:2023cv00048 |
| January 13, 2023 |
| US District Court for the District of Delaware |
| Colm F Connolly |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. ยง 271 Patent Infringement |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on February 1, 2023. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 10 WAIVER OF SERVICE returned executed by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH: For Hetero Labs Limited Unit-V waiver sent on 2/1/2023, answer due 4/3/2023. (Dellinger, Megan) |
| Filing 9 WAIVER OF SERVICE returned executed by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH: For Hetero Labs Limited waiver sent on 2/1/2023, answer due 4/3/2023. (Dellinger, Megan) |
| Filing 8 WAIVER OF SERVICE returned executed by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH: For Hetero USA Inc. waiver sent on 2/1/2023, answer due 4/3/2023. (Dellinger, Megan) |
| Filing 7 STANDING ORDER REGARDING BRIEFING IN ALL CASES (nmf) |
| Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. (rjb) |
| Filing 6 Summons Issued as to Hetero Labs Limited on 1/13/2023; Hetero Labs Limited Unit-V on 1/13/2023; Hetero USA Inc. on 1/13/2023. (Attachments: #1 Summons Issued, #2 Summons Issued)(srs) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent C. H. Boehringer Sohn AG & Co. KG for Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, and Boehringer Ingelheim Pharmaceuticals Inc. filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc. (srs) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,486,526 B2 ;10,034,877 B2. (srs) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: December 5, 2022. Date of Expiration of Patent: August 5, 2029.Thirty Month Stay Deadline: 6/5/2025. (srs) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (srs) |
| Filing 1 COMPLAINT filed against Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc. ( Filing fee $ 402, receipt number ADEDC-4044243.) - filed by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH. (Attachments: #1 Exhibit 1-2, #2 Civil Cover Sheet)(srs) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
